December 6, 2018


Contact: Paul Lucking





Collaboration Promises Better, More Accurate Breast Cancer Diagnostics

Data-sharing results in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results.


Nashville, TN:  The Health Exchange Market, or T.H.E.M.™, together with LabCorp (NYSE: LH), Konica Minolta, Inc. (Japan), University of Rochester, Penn State Hershey Medical Center and Lebanon VA Medical Center, has presented significant findings in breast cancer research at the 2018 San Antonio Breast Cancer Symposium®.  The study (Number 851014) is titled: ASCO/CAP human epidermal growth factor receptor-2 (HER2) in situ hybridization (ISH) categories evaluated by quantitative HER2 protein diagnostic methodologies: A comparative analysis.


Each year, over 20,000+ women with HER2 Positive Breast Cancer in the US are in danger of being misdiagnosed and subsequently mistreated.  T.H.E.M. identified the research project needs and appropriate study members, and helped facilitate the analysis using new and historical companion data. The effort was successful in improving the diagnostic accuracy by 20% in stage 3 and stage 4 patients. The entire project was completed in under four months, thanks to the cooperation of all study members.


“We are pleased to help facilitate such an impactful study and remain steadfast in our commitment that the healthcare community can accomplish greater transformation through sharing data that would otherwise be impossible to do single-handedly.” says T.H.E.M.™, Founder and CEO, Collin Powell. "We want to thank everyone for their participation in this collaborative effort, as well as the The San Antonio Breast Cancer Symposium® for helping to raise awareness that is instrumental to secure patient adoption efforts. We are hopeful these findings will not only aid with ongoing research efforts aimed at breast cancer prevention and maintenance, but will eventually lead to the eradication of this disease.”


ABOUT​ ​​​The​ ​Health​ ​Exchange​ ​Market​ ​(T.H.E.M.™):


T.H.E.M.™ ​is​ ​a global bio-bank and repository for de-identified healthcare data, providing a​​ ​commercial​ ​marketplace​ ​that​ ​allows​ ​health​ ​data owners​ ​to​ ​create​ ​new​ ​and​ ​ongoing​ ​revenue​ ​streams​ ​from​ ​​existing​ ​data,​ ​and​ ​provides​ ​buyers​ ​with​ ​a smarter,​ ​cost​ ​effective​ ​solution​ ​to​ ​obtaining​ ​larger​ ​and​ ​more​ ​complete​ ​data​ ​sets​ ​from​ ​multiple​ ​sources. ​To​ ​learn​ ​more​ ​about​ ​T.H.E.M.™,​ ​write​ ​to​ ​​​​ ​or​ ​visit​ ​us​ ​at


About Laboratory Corporation of America Holdings:


LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit


About Konika Milonolta, Inc:

Konica, Minolta Inc, Bio Health Care Business Development Division, Corporate R&D Headquarter, No. 1 Sakura-machi, Hino-shi Tokyo 191-8511, Japan ​​ Konika Milonolta reported net revenues of over $15.8 Billion in 2017.

Download the press release here:

THEM Press Release December 5, 2018

View the poster mentioned in the press release here:

HER2 ISH Comparative Analysis